Orchestra BioMed Holdings, Inc.

OBIOHealthcare · BiotechnologyVisit siteCIK 0001814114

Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.): $322.2M
Price: $5.36
% Change (Daily % change from the live per-ticker quote feed.): -1.29%
Volume: 276.7K

About

Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.

Quick stats

Shares outstanding60.1M

Computed float31.2M

Float / shares51.9%

Key info

SectorHealthcare

IndustryBiotechnology

CIK0001814114

Websitehttps://orchestrabiomed.com

AI Summary

AI-generated

1/17

3d ago

minorneutraloperations update

Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference

Orchestra BioMed announced that Chairman and CEO David Hochman will present at the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026.

Management will also host one-on-one meetings with investors on September 9 and September 10 in conjunction with the event.

A live webcast of the presentation will be available via the company's Investor Relations website, with a replay to follow.